PRVB · Provention Bio, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|
| Revenue | $12.89M | $1.40M | - | - | - |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| R&D | $75.80M | $69.63M | $66.36M | $36.36M | $7.68M |
| SG&A | $33.33M | $47.35M | $33.33M | $8.01M | $1.46M |
| Total Operating Expenses | $141.06M | $116.97M | $99.69M | $44.37M | $9.14M |
| D&A | $33.0K | $387.0K | $33.0K | - | - |
| Operating Income | ($128.16M) | ($115.58M) | ($99.69M) | ($44.37M) | ($9.14M) |
| Interest Expense | $1.04M | - | - | - | - |
| Income Tax | ($13.39M) | ($1.00M) | ($523.0K) | - | ($187.0K) |
| Net Income | ($113.56M) | ($114.43M) | ($98.58M) | ($43.28M) | ($9.13M) |
| EPS - Basic | ($1.88) | - | - | - | - |
| EPS - Diluted | - | - | - | - | - |
Balance Sheet
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|
| Cash & Equivalents | $44.04M | $78.19M | $102.29M | $39.16M | $58.54M |
| Accounts Receivable | $1.36M | - | - | - | - |
| Inventory | $1.23M | - | - | - | - |
| Accounts Payable | $6.76M | $3.55M | $7.57M | $1.77M | $568.0K |
| Current Assets | $174.65M | $101.10M | $126.55M | - | - |
| Total Assets | $236.86M | $135.62M | $128.52M | $86.00M | $61.53M |
| Current Liabilities | $90.39M | $22.79M | $16.73M | $3.84M | $1.87M |
| Long-term Debt | $23.47M | - | - | - | - |
| Total Liabilities | $115.01M | $24.89M | $3.84M | - | $1.87M |
| Stockholders' Equity | $121.85M | $110.73M | $111.07M | $82.16M | ($165.0K) |
| Retained Earnings | ($405.64M) | ($292.07M) | ($177.64M) | ($79.06M) | ($35.78M) |
Cash Flow
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|
| Operating Cash Flow | ($75.41M) | ($95.39M) | ($76.34M) | ($36.06M) | ($4.88M) |
| Investing Cash Flow | ($88.13M) | ($31.10M) | $25.17M | ($46.25M) | - |
| Financing Cash Flow | $129.38M | $102.38M | $114.29M | $62.94M | $26.72M |
| CapEx | $795.0K | $961.0K | $1.11M | - | - |
| Free Cash Flow | ($76.20M) | ($96.35M) | ($77.45M) | - | - |
Ratios
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | - | - | - | - | - |
| Operating margin | -993.9% | -8285.2% | - | - | - |
| EBITDA margin | -993.6% | -8257.4% | - | - | - |
| Net margin | -880.7% | -8203.0% | - | - | - |
| Free cash flow margin | -590.9% | -6906.5% | - | - | - |
| FCF / Net income | 0.67 | 0.84 | 0.79 | - | - |
| R&D / Revenue | 587.9% | 4991.2% | - | - | - |
| SG&A / Revenue | 258.4% | 3394.0% | - | - | - |
| Effective tax rate | - | - | - | - | - |
| Return on assets | -47.9% | -84.4% | -76.7% | -50.3% | -14.8% |
| Return on equity | -93.2% | -103.3% | -88.8% | -52.7% | 5535.2% |
| Return on invested capital | -69.7% | - | - | - | - |
| Liquidity | |||||
| Current ratio | 1.93 | 4.44 | 7.56 | - | - |
| Quick ratio | 1.92 | 4.44 | 7.56 | - | - |
| Cash ratio | 0.49 | 3.43 | 6.11 | 10.20 | 31.29 |
| Leverage | |||||
| Debt / Equity | 0.19 | - | - | - | - |
| Debt / Assets | 0.10 | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - |
| Interest coverage | -123.6x | - | - | - | - |
| Equity multiplier | 1.94 | 1.22 | 1.16 | 1.05 | -372.90 |
| Liabilities / Assets | 0.49 | 0.18 | 0.03 | - | 0.03 |
| Efficiency | |||||
| Asset turnover | 0.05 | 0.01 | - | - | - |
| Inventory turnover | - | - | - | - | - |
| Days sales outstanding | 38d | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - |
| Valuation | |||||
| P / E | - | - | - | - | - |
| P / B | - | - | - | - | - |
| P / S | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - |
| Growth | |||||
| Revenue growth (YoY) | 824.4% | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - |
| Operating income growth (YoY) | -10.9% | -15.9% | -124.7% | -385.5% | - |
| Net income growth (YoY) | 0.8% | -16.1% | -127.7% | -373.9% | - |
| EPS growth (YoY) | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - |
| FCF growth (YoY) | 20.9% | -24.4% | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - |
| Book value growth (YoY) | 10.0% | -0.3% | 35.2% | - | - |
Stability scores
Altman Z′
FY 2022 · bankruptcy risk
-2.38
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2022 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- -No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Provention Bio against the 5 most active filers in the same SIC group.